Successful treatment of meticillin-resistant Staphylococcus aureus bacteraemia in a neonate using daptomycin.
Daptomycin is licensed for the management of Staphylococcus aureus infections in adults, including those caused by meticillin-resistant S. aureus (MRSA). Few data exist on paediatric use or dose guidance in neonates. We report the case of a neonate with MRSA bacteraemia successfully managed with daptomycin. Dose requirements were substantially higher than those recommended for adults.
Department of Clinical Microbiology, University Hospitals of Leicester NHS Trust, Leicester LE1 5WW, UK.
Abid
A
Hussain
Department of Child Health, University Hospitals of Leicester NHS Trust, Leicester LE1 5WW, UK.
Venkatesh
V
Kairamkonda
Department of Clinical Microbiology, University Hospitals of Leicester NHS Trust, Leicester LE1 5WW, UK.
David Richard
DR
Jenkins
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016470:Bacteremia / Q000188:drug therapy* / Q000382:microbiology*; D017576:Daptomycin / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus / Q000302:isolation & purification*; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D017576:Daptomycin